{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:58:47Z","timestamp":1791104327183,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.parkreldis.2010.02.006","type":"journal-article","created":{"date-parts":[[2010,3,12]],"date-time":"2010-03-12T13:11:27Z","timestamp":1268399487000},"page":"334-337","source":"Crossref","is-referenced-by-count":45,"title":["Long term follow-up of Parkinson's disease patients with impulse control disorders"],"prefix":"10.1016","volume":"16","author":[{"given":"Melis","family":"Sohtao\u011flu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya Yavuz","family":"Demiray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclay","family":"Kenangil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"\u00d6zekmek\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethem","family":"Ergin\u00f6z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2010.02.006_bib1","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archneur.63.7.969","article-title":"Association of dopamine agonist use with impulse control disorders in Parkinson's disease","volume":"63","author":"Weintraub","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1212\/01.wnl.0000238401.76928.45","article-title":"Clinical features associated with impulse control disorders in Parkinson disease","volume":"67","author":"Pontone","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib3","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1212\/01.wnl.0000218206.20920.4d","article-title":"Prospective prevalence of pathological gambling and medication association in Parkinson's disease","volume":"66","author":"Voon","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/NRL.0b013e31816606a7","article-title":"Impulse control disorders and pathological gambling in patients with Parkinson disease","volume":"14","author":"Stamey","year":"2008","journal-title":"Neurologist"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/mds.20757","article-title":"Compulsive eating and weight gain related to dopamine agonist use","volume":"21","author":"Nirenberg","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.wco.0000137528.23126.41","article-title":"Dopamine dysregulation syndrome in Parkinson's disease","volume":"17","author":"Evans","year":"2004","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","article-title":"Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies","volume":"68","author":"Giovannoni","year":"2000","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib8","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1212\/01.wnl.0000184487.72289.f0","article-title":"Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson's disease","volume":"65","author":"Evans","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib9","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/mds.21611","article-title":"Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series","volume":"22","author":"Gallagher","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib10","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archneur.62.9.noc50009","article-title":"Pathological gambling caused by drugs used to treat Parkinson disease","volume":"62","author":"Dodd","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib11","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.parkreldis.2006.02.004","article-title":"Dopamine agonist therapy for Parkinson disease and pathological gambling","volume":"12","author":"Imamura","year":"2006","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib12","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I","article-title":"Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?","volume":"15","author":"Molina","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib13","unstructured":"Kenangil G, \u00d6zekmek\u00e7i S, Sohtaoglu M, Ergin\u00f6z E. Compulsive behaviors in patients with Parkinson's disease. Neurologist, in press."},{"key":"10.1016\/j.parkreldis.2010.02.006_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.21770","article-title":"Long-term follow-up of impulse control disorders in Parkinson's disease","volume":"23","author":"Mamikonyan","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib15","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/1531-8257(199909)14:5<836::AID-MDS1018>3.0.CO;2-0","article-title":"Punding on L-Dopa","volume":"14","author":"Fernandez","year":"1999","journal-title":"Mov Disord"},{"issue":"Suppl. 1","key":"10.1016\/j.parkreldis.2010.02.006_bib16","first-page":"S90","article-title":"Pathological gambling in Parkinson's disease","volume":"5","author":"Molina","year":"1999","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00002826-198910000-00002","article-title":"Hypersexuality with antiparkinsonian therapy","volume":"12","author":"Uitti","year":"1989","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib18","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1212\/WNL.42.6.1142","article-title":"What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study","volume":"42","author":"Hughes","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib19","series-title":"Recent developments in Parkinson's disease","first-page":"153","article-title":"Members of the UPDRS development committee. Unified Parkinson's disease rating scale","author":"Fahn","year":"1987"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","article-title":"Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors","volume":"123","author":"Fenelon","year":"2000","journal-title":"Brain"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1212\/WNL.52.6.1227","article-title":"Switching dopamine agonists in advanced Parkinson's disease. Is rapid titration preferable to slow?","volume":"52","author":"Goetz","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib22","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/mds.20210","article-title":"Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table","volume":"19","author":"Grosset","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF02938408","article-title":"Management of impulse control disorders in Parkinson's disease","volume":"9","author":"Galpern","year":"2007","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00004850-200607000-00002","article-title":"Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation","volume":"21","author":"Grant","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib25","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.parkreldis.2007.11.008","article-title":"Topiramate in managing impulse control disorders in Parkinson's disease","volume":"14","author":"Bermejo","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib26","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/mds.22439","article-title":"Treatment of hypersexuality in Parkinson's disease with carbamazepine\u2013a case report","volume":"24","author":"Bach","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/archneur.64.2.212","article-title":"Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease","volume":"64","author":"Voon","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib28","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/mds.21702","article-title":"Predictors of punding in Parkinson's disease: results from a questionnaire survey","volume":"22","author":"Lawrence","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0269881106073109","article-title":"New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease:the role of dopamine agonist treatment and age at motor symptoms onset","volume":"21","author":"Giladi","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.parkreldis.2010.02.006_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.parkreldis.2007.05.006","article-title":"Predictors of impulsivity and reward seeking behavior with dopamine agonists","volume":"14","author":"Ondo","year":"2008","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802010000441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802010000441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T16:53:11Z","timestamp":1544633591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802010000441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S1353802010000441"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2010.02.006","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}